...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >Progressive Multifocal Leukoencephalopathy: Current Insights
【24h】

Progressive Multifocal Leukoencephalopathy: Current Insights

机译：渐进式多焦点白血病：当前见解

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.
机译：应根据易感因素评估PML病例，因为这些亚组因入射率，临床过程和预后而异。对于PML风险的三个最重要的群体是血液恶性肿瘤的患者，主要以前用免疫治疗，但也未处理，艾滋病毒感染患者，以及使用单克隆抗体（MAB）治疗的患者。流行病学数据是稀缺和部分冲突，但亚组的分布似乎发生了变化。虽然没有特异性抗JCPYV治疗，但免疫功能的恢复是PML治疗最有效的方法。有必要进行研究以确定免疫检查点抑制剂是否可以使某些PML子组受益。除了接受Navalizumab（NTZ）的MS患者外，没有系统的国家或风险分层算法的系统国家或国际记录。需要这些，以改善PML风险评估，并定制更好的预防策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号